Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
17 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
28 Mar 24
8-K
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
19 Mar 24
8-K
Termination of a Material Definitive Agreement
1 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4 Jan 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
8-K
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
6 Dec 23
8-K
Regulation FD Disclosure
4 Dec 23
8-K
Regulation FD Disclosure
29 Nov 23
8-K
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
31 Oct 23
8-K
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
16 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Other Events
15 Jun 23
424B5
Prospectus supplement for primary offering
15 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
12 Jun 23
EFFECT
Notice of effectiveness
30 May 23
S-3/A
Shelf registration (amended)
24 May 23
CORRESP
Correspondence with SEC
24 May 23
UPLOAD
Letter from SEC
19 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
15 May 23
S-3
Shelf registration
12 May 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
24 Apr 23
8-K
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
10 Apr 23
8-K
Other Events
4 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
8-K
Regulation FD Disclosure
15 Mar 23
8-K
Regulation FD Disclosure
9 Jan 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
26 Oct 22
8-K
Amendments to Articles of Incorporation or Bylaws
3 Oct 22
8-K
Regulation FD Disclosure
12 Sep 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
15 Aug 22
8-K
Departure of Directors or Certain Officers
29 Jul 22
Latest ownership filings
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
4
PHILLIP MD ET AL FROST
20 Jul 23
4
Anthony J Japour
20 Jul 23
4
James Joseph Martin
20 Jul 23
4
Roger D. Kornberg
20 Jul 23
4
Sam Lee
20 Jul 23
4
RICHARD C PFENNIGER JR
20 Jul 23
4
Fred Hassan
20 Jul 23
4
Steven D Rubin
20 Jul 23
3
Fred Hassan
27 Apr 23
SC 13D/A
FROST PHILLIP MD ET AL
14 Apr 23
SC 13G
Hassan Fred
12 Apr 23
4
PHILLIP MD ET AL FROST
6 Apr 23
SC 13G/A
SABBY MANAGEMENT, LLC
10 Jan 23
4
Anthony J Japour
3 Aug 22
4
James Joseph Martin
3 Aug 22
4
RICHARD C PFENNIGER JR
3 Aug 22
4
PHILLIP MD ET AL FROST
3 Aug 22
4
Steven D Rubin
3 Aug 22
4
Roger D. Kornberg
3 Aug 22
4
Sam Lee
3 Aug 22
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
10 Feb 22
SC 13G/A
SABBY MANAGEMENT, LLC
3 Jan 22
4
RICHARD C PFENNIGER JR
23 Aug 21
4
RICHARD C PFENNIGER JR
20 Jul 21
4
Roger D. Kornberg
20 Jul 21
4
James Joseph Martin
20 Jul 21
4
Steven D Rubin
20 Jul 21
4
Anthony J Japour
20 Jul 21
4
Sam Lee
20 Jul 21
4
PHILLIP MD ET AL FROST
20 Jul 21
SC 13D/A
FROST PHILLIP MD ET AL
10 Jun 21
3
RICHARD C PFENNIGER JR
2 Jun 21
SC 13D
FiveT Investment Management Ltd
25 May 21
SC 13G
Ayrton Capital LLC
17 May 21
SC 13G
SABBY MANAGEMENT, LLC
12 May 21
4
Raymond F Schinazi
6 May 21
SC 13G/A
CVI Investments, Inc.
16 Feb 21
5
Sam Lee
12 Feb 21
SC 13G
RENAISSANCE TECHNOLOGIES LLC
10 Feb 21